Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-16
2006-05-16
Morris, Patricia L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S118000
Reexamination Certificate
active
07045529
ABSTRACT:
Provided herein are compounds of the formula (I):as well as stereoisomers and pharmaceutically acceptable salts thereof. Such compounds are, because of their ability to antagonize CRF, useful in the treatment of a variety of disorders characterized by execssive CRF expression. These include, for example: affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis and hypoglycemia.
REFERENCES:
patent: 4950802 (1990-08-01), Nader
patent: 5446160 (1995-08-01), Stucky et al.
patent: 6362180 (2002-03-01), Wilde et al.
patent: 6642230 (2003-11-01), Wilde et al.
patent: WO 95/10506 (1995-04-01), None
patent: WO 95/33727 (1995-12-01), None
patent: WO 95/33750 (1995-12-01), None
patent: WO 95/34563 (1995-12-01), None
patent: WO 98/35967 (1998-08-01), None
Arató, M., et al., “Elevated CSF CRF in suicide victims,”Biol. Psychiatry,1989, 25, 355-359.
Banki, C.M., et al., “CSF corticotrophin-releasing factor-like immunoreactivity in depression and schizophrenia,”Am. J. Psychiatry,1987, 144(7), 873-877.
Berridge, C.W., et al., “A corticotrophin-releasing factor antagonist reverses the stress-induced changes of exploratory behavior in mice,”Horm.&Behav.,1987, 21, 393-401.
Berridge, C.W., et al., “Corticotropin-releasingfactor elicits naloxone sensitive stress-like alterations in exploratory behavior in mice,”Regul. Peptides,1986, 16, 83-93.
Blalock, J.E., “A molecular basis for bidirectional communication between the immune and neuroendocrine systems,”Physiological Reviews,1989, 69(1), 1-32.
Britton, D.R., et al., “Intraventricular corticotrophin-releasing factor enhances behavioral effects of novelty,”Life Sci.,1982, 31, 363-367.
Britton, K.T., et al., “Chlordiazepoxide attenuates response suppression induced by corticotrophin-releasing factor in the conflict test,”Psychopharmacology,1985, 86, 170-174.
Britton, K.T., et al., “Corticotropin releasing factor and amphetamine exaggerate partial agonist properties of benzodiazepine antagonist Ro 15-1788,”Psychopharmacology,1988, 94, 306-311.
Brown, D.J., et al., “Purine studies. Part XI. Condensation of tetraethoxymethanine and similar orthocarbonates withortho-diamines to give 8-ethoxypurines and related fused imidazoles,”J. Chem. Soc., Perkin Trans.,1974, 1, 349-352.
Camps, F., et al., “A simple method for preparation of Aryl 2,2,2-Tri-fluoroethyl ethers,”Synthesis,1980, pp. 727-728.
De Souza, E.B., et al., “Corticotropin-releasing factor receptors and widely distributed within the rat central nervous system: an autoradiographic study,”J. Neurosci.,1985, 5(12), 3189-3203.
De Souza, E.B., “CRH defects in alzheimer's and other neurologic diseases,”Hosp. Practice,1988, 23, 59-71.
Dunn, A.J., et al., “Physiological and behavioral responses to corticotrophin-releasing factor administration: is CRF a mediator of anxiety or stress responses?, ”Brain Res. Rev.,1990, 15, 71-100.
France, R.D., et al., “CSF corticotrophin-releasing factor-like immunoactivity in chronic pain patients with and without major depression,”Biol. Psychiatry,1988, 23, 86-88.
Gold, P.W., et al., “Psychiatric implications of basic and clinical studies with corticotrophin-releasing factor,”Am. J. Psychiatry,1984, 141(5), 619-627.
Gold., P.W., et al., “responses to corticotrophin-releasing hormone in the hypercortisolism of depression and cushing's disease,”New Eng. J. Med.,1986, 314(21), 1329-1335.
Grigoriadis, D.E., et al., “Effects of chronic antidepressant and benzodiazepine treatment on corticotrophin-releasing-factor receptors in rat brain and pituitary,”Neuropsychopharmacology,1989, 2(1), 53-60.
Grimmett, M.R., “Imidazoles and their benzo derivatives: (iii) synthesis and applications,”Comprehensive Heterocyclic Chemistry, Pergamon Press,1984, vol. 5, Part 4A, Katritzky A.R., et al. (Eds.),457-498.
Grinberg, V.A., et al., “Electrochemical perfluoroalkoxylation of aromatic compounds,” Russian Chem. Bull., 1997, 46(8), 1441-1444.
Holsboer, F., et al., “Acth and multisteroid responses to corticotrophin-releasing factor in depressive illness: relationship to multisteroid responses after acth stimulation and dexamethasone suppression,”Psychoneuroendocrinology,1984, 9(2), 147-160.
Huynh, C., et al., “Copper-catalysed reactions of grignard reagents with epoxides and oxetane,”Tetrah. Letts.,1979, 17, 1503-1506.
Koob, G.F., et al., inCorticotropin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide,De Souza, E.B., et al. (Eds.),CRC Press,1990, 17, 253-265.
Koob, G.F., “Stress, corticotrophin-releasing factor, and behavior,”Persp. On Behav. Med.,1985, 2, 39-52.
Kuroboshi, M., et al., “Oxidative desulfurization-fluorination of xanthates. A convenient synthesis of trifluoromethyl ethers and difluoro(methylthio)methyl ethers,”Tetrah. Letts.,1992, 33(29), 4173-4176.
Mathey, F., et al., “Reaction De MoF6avec les chlorothioformiates d'aryle nouvelle synthese des aryl trifluoromethylethers ArOCF3, ”Tetrah. Letts.,1973, 25, 2253-2256.
Mitsunobu, O., “The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products,”Synthesis,1981, 1-28.
Montgomery, J.A., et al., “Synthesis of potential anticancer agents. XXII. Reactions of orthoesters with 4,5-diaminopyrimidines,”J. Org. Chem.,1960, 25, 395-399.
Morley, J.E., “Minireview—neuropeptides: conductors of the immune orchestra,”Life Sci.,1987, 41, 527-544.
Negishi, E.-I., et al., “Selective carbon-carbon bond formation via transition metal catalysis 3.1A highly selective synthesis of unsymmetrical biaryls and diarylmethanes by the nickel-or palladium-catalyzed reaction of aryl-and benzylzinc derivaives with aryl halides,”J. Org. Chem.,1977, 42(10), 1821-1823.
Nemeroff, C.B., et al., “Elevated concentrations of SF corticotrophin-releasing factor-like immunoreactivity in depressed patients,”Science,1984, 226, 1342-1344.
Nemeroff, C.B., et al., “Reduced corticotrophin releasing factor binding sites in the frontal cortex of suicide victims,”Arch. Gen. Psychiatry,1988, 45, 577-579.
Preschler, D., et al., “Various synthetic approaches to fluoroalkyl p-nitrophenyl ethers,”J. Fluorine Chem.,1996, 79, 145-148.
Remington's Pharmaceutical Sciences,17thEd.,Mack Publishing Co.,1985, p. 1418.
Rivier, J., et al., “Characterization of rat hypothalamic corticotrophin-releasing factor,”Proc. Nat. Acad. Sci. USA,1983, 80, 4851-4855.
Sapolsky, R.M., “Hypercortisolism among socially subordinate wild baboons originates at the CNS level,”Arch. Gen. Psychiatry,1989, 46, 1047-1051.
Sato, M., et al., “Cross-coupling reaction of alkyl- or arylboronic acid esters with organic halides induced by thallium(I) salts and palladium-catalyst,”Chem. Letts.,1989, 1405-1408.
Shelyazhenko, S.V., et al., “Synthesis and reactions of difluromethoxy- and difluorochloromethoxy derivatives of benzene,”J. Org. Chem.(Russia), 1992, 28(8), 1317-1323.
Swerdlow, N.R., et al., “Corticotropin-releasing factor potentiates acoustic startle in rats: blockade by chlordiazepoxide,”Psychopharmacology,1986, 88, 147-152.
Vale, W., et al., “Chemical and biological characterization of co
Arvanitis Argyrios
Bakthavatchalam Rajagopal
Beck James P.
Wilde Richard G.
Bristol--Myers Squibb Company
Makujina Shah R.
Morris Patricia L.
LandOfFree
Imidazopyrimidinyl and imidazopyri dinyl derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazopyrimidinyl and imidazopyri dinyl derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazopyrimidinyl and imidazopyri dinyl derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3614135